[ic] Stox Profiler

[Terry]

STock Pick for month of JULY

Get NWLF First Thing Monday, This Is Going To Explode next 2-5 days

Speculative TARGET_PRICE IN NEXT 3-5 DAYS: $3.75 - 4.90
Speculative TARGET_PRICE IN NEXT 10 DAYS: $6.15

OTCBB: NWLF - New Life Scientific, Inc


CURRENT_PRICE: $1.80 GET IN NOW!

Speculative TARGET_PRICE IN NEXT 3-5 DAYS: $3.75 - 4.90
Speculative TARGET_PRICE IN NEXT 10 DAYS: $6.15


News Released Friday: New Life Scientific, Inc. Information to Be Available through S&P Market Access Program
News Released Friday: New Life Scientific, Inc. Information to Be Available through S&P Market Access Program


Before we start with the profile of NWLF we would like
to mention something very important: There is a Big PR
Campaign starting on Monday . And it will go all week 
so it would be best to get in NOW


Expect Huge news in very near future.

==========+>+>+> Company Profile +>+>+>==============

OTCBB: NWLF - New Life Scientific, Inc

Symbol: NWLF.OB
CURRENT_PRICE: $1.80 GET IT NOW!

Speculative TARGET_PRICE IN NEXT 3-5 DAYS: $3.75 - 4.90
Speculative TARGET_PRICE IN NEXT 10 DAYS: $6.15


How many times have you seen good stocks but you couldn't
get your hands on them in the right moment? We are alerting
you to a special company with a unique product that is set
to be profiled by many newsletters in the next 5-10 days
-- this is your chance to get in!

==========+>+>+> Company Profile +>+>+>==============

About the Company<--------------


NWLF recently acquired Novo Life Scientific (Ukraine), the holder of a cooperation agreement with the Institute of Molecular Biology and Genetics of the Ukrainian Academy of Sciences (IMBG).
Novo Life Scientific, in conjunction with IMBG, highly regarded for its extensive knowledge and expertise in the fields of molecular cell biology and molecular genetics research, intends to develop and market certain stem cell related products and therapies and to establish a stem cell bank based in Europe.
The company intends to take of advantage of the extensive research previously conducted in Ukraine by IMBG. New Life is also in the process of acquiring Pharma Trials, Inc. (PTI), a provider of clinical trials, market research and regulatory approval of products for pharmaceutical companies and Contract Research Organizations.
In addition, New Life has signed a strategic alliance agreement with INVAPHARM, LLC of Malvern, PA. INVAPHARM has expertise in drug delivery, development of pharmaceutical products and is the holder of licenses for various pharmaceutical products and drug delivery systems. 

|

read this legal info below
--------------------------
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.
Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice.
Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the witer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say.
Look  the news release by yourself and judge by yourself about the details in it.

In compliance with Section 17(b), we disclose the holding of 60 000 NWLF shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares.
Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements. 

Please be advised that nothing within this email shall constitute a solicitation or an invitation to get position in or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. This newsletter was paid $54400 from third party  to send this report.  All statements made are our express opinion only and should be treated as such. We may own, take position and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" , "speculative target price" and "intend" or similar terms.